Amgen’s Phase III TRINOVA-1 trial of recurrent ovarian cancer drug yields positive results
The global, multicenter, double-blind study involved administering trebananib plus paclitaxel or placebo plus paclitaxel to more than 900 women suffering from recurrent partially platinum-sensitive or resistant epithelial ovarian,